Business Context and Reporting Period
Company: Lexaria Bioscience Corp. (Lexaria Corp.)
Filing Type: Form 8-K (Current Report)
Date of Report: November 12, 2014
Event: Entry into a Material Definitive Agreement to acquire a controlling interest in PoViva, a business focused on CBD-based products.
Key Financial Metrics and Transaction Terms
This filing details a structured acquisition agreement rather than standard periodic financial results. Key financial terms include:
- Initial Acquisition: Lexaria acquires 51% of PoViva.
- Initial Cash Consideration: $50,000 paid to the Operations bank account.
- Committed Spend: $75,000 to be spent over one year following execution.
- Equity Consideration: $25,000 worth of Lexaria common shares issued to Founders (subject to a six-month lockup).
- Consulting Fees: $2,000/month for production consulting and $2,000/month for marketing consulting for 12 months (payable from revenues, operating account, or marketing budget).
- Performance Bonus: $50,000 cash bonus to Founders if PoViva generates $300,000 in sales within 8 months.
- Future Acquisition Option: Lexaria may acquire an additional 24% (totaling 75% ownership) by spending $100,000 on sales and marketing and paying 2.5 times the trailing 12-month revenue (pro-rata). Up to 50% of this payment may be made in Lexaria stock.
Note: The filing does not provide standalone revenue, profit, cash flow, or debt metrics for Lexaria or PoViva.
Material Changes and Strategic Outlook
Strategic Shift: The agreement marks Lexaria's entry into the CBD-based product market through the acquisition of PoViva's business assets and intellectual property.
Intellectual Property: Upon expiration of the agreement terms, Founders receive a lifetime personal license to produce products covered by patent numbers #62010621 and #62037706. This license is non-transferable to third parties competing with PoViva or Lexaria.
Supply Chain Rights: PoViva is granted a Right of First Refusal for "white-label" production of additional CBD products for Lexaria, though Lexaria retains the discretion to engage other producers if PoViva is deemed uncompetitive.
Risks and Contingencies
- Performance Contingency: A significant portion of the founder compensation ($50,000 bonus) is contingent on achieving $300,000 in sales within 8 months.
- Future Option Validity: The option to acquire the additional 24% stake is valid only between November 15, 2015, and November 15, 2017.
- Capital Commitment: The transaction requires specific future cash outlays ($75,000 initial spend, potential $100,000 marketing spend) which may impact liquidity if not met.
Investor Verification Checklist
- Verify the current cash position of Lexaria to ensure it can meet the immediate $50,000 payment and the $75,000 committed spend.
- Confirm the valuation of the $25,000 worth of Lexaria common shares issued to Founders based on the stock price at the time of issuance.
- Monitor PoViva's sales performance over the next 8 months to assess the likelihood of the $50,000 performance bonus payout.
- Review the validity and status of patent numbers #62010621 and #62037706.
- Assess the competitive landscape for CBD product production to evaluate the risk of Lexaria exercising its right to bypass PoViva for future manufacturing.